Multisystem inflammatory syndrome in children (MIS-C) is a novel post-infectious inflammatory condition associated with Coronavirus disease 2019 (COVID-19), characterized by prolonged fever, gastrointestinal (GI) symptoms and rash.¹ To some extent, the disease resembles Kawasaki disease (KD), toxic shock syndrome (TSS), and hemophagocytic lymphohistiocytosis (HLH), increasing the difficulty in differential diagnosis in clinical practice.¹ In an interview with Omnihealth Practice, Dr. Cheung, Wai-Yin Eddie discussed the challenge of evaluating suspected MIS-C cases in real-life scenarios and emphasized the importance of timely intervention among children who were infected with or recently recovered from COVID-19. He also shared a clinical case of a 7-year-old girl with MIS-C who presented with early MIS-C symptoms and was managed with immunomodulatory treatment, swiftly achieving favorable outcomes.

Eczema, also known as atopic dermatitis (AD), is a chronic, relapsing, inflammatory skin disease characterized by intense itch, recurrent eczematous lesions, and a fluctuating course.^1,2 Statistics showed that up to 20% of children are affected by AD worldwide, while 15% of secondary school children in Hong Kong are reported to have the problem.^3,4 In addition, evidence has suggested the prevalence of AD in Asia is on the rise.² Although AD can be controlled through various proven strategies, optimizing AD management is still a challenge since certain situations, such as steroid phobia and poor patient compliance, could lead to treatment failure.⁴ In these regards, an algorithm for the topical AD treatment was developed and published in 2020 for use by the primary care physicians, pediatricians, and dermatologists in South and East Asia.² In the interviews with Omnihealth Practice, Dr. Luk, Chi-Kong David and Professor Hon, Kam-Lun Ellis, authors of the practical recommendations, discussed the difficulties in managing mild-to-moderate AD, and shared their views on improving treatment outcomes in these AD patients.